Thinly traded micro cap Kezar Life Sciences (NASDAQ:KZR) is up 2% after hours on the heels of positive data from the Phase 1b open-label dose-escalation portion of its Phase 1/2 study of KZR-616 in patients with systemic lupus erythematosus (SLE). The results were presented at EULAR in Madrid.
The immunoproteasome inhibitor was well-tolerated while demonstrating encouraging immunomodulatory activity across multiple measures.
The Phase 2 portion should launch shortly. Phase 2 studies in dermatomyositis, polymyositis, autoimmune hemolytic anemia and immune thrombocytopenia will commence in H2.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.